



Oregon and Utah

Independent licensees of the Blue Cross and Blue Shield Association



Idaho and select counties of Washington

## Medication Policy Manual

**Policy No:** dru425

**Topic:** High-Cost Oral Antipsychotics:

**Date of Origin:** October 9, 2015

- asenapine (Saphris®)
- brexpiprazole (Rexulti®)
- cariprazine (Vraylar™)
- iloperidone (Fanapt®)
- lurasidone (Latuda®)
- paliperidone (oral) (Invega®, generic paliperidone)
- quetiapine ER (oral) (generic, Seroquel XR®)

**Committee Approval Date:** October 13, 2017

**Next Review Date:** October 2018

**Effective Date:** November 1, 2017

### IMPORTANT REMINDER

This Medication Policy has been developed through consideration of medical necessity, generally accepted standards of medical practice, and review of medical literature and government approval status.

Benefit determinations should be based in all cases on the applicable contract language. To the extent there are any conflicts between these guidelines and the contract language, the contract language will control.

The purpose of medication policy is to provide a guide to coverage. Medication Policy is not intended to dictate to providers how to practice medicine. Providers are expected to exercise their medical judgment in providing the most appropriate care.

### Description

Asenapine (Saphris®), brexpiprazole (Rexulti®), cariprazine (Vraylar™), iloperidone (Fanapt®), lurasidone (Latuda®), paliperidone oral (Invega®, generic paliperidone), and quetiapine extended-release (ER) oral (Seroquel XR®, generic quetiapine ER) are oral antipsychotics used to treat schizophrenia. Many of these medications may also be used to treat other conditions such as bipolar disorder, Tourette's syndrome, agitation with autistic disorder, and as an add-on treatment to antidepressant medications for treatment of major depressive disorder (MDD).

**This policy does not apply to injectables, such as aripiprazole (Abilify Maintena®, Aristada®), olanzapine (Zyprexa Relprevv®), paliperidone (Invega Sustenna®, Invega Trinza®), or risperidone (Risperdal Consta®).**

## Policy/Criteria

- I. Most contracts require prior authorization approval of oral high-cost antipsychotics prior to coverage. Oral high-cost antipsychotics may be considered medically necessary when at least two low-cost generic antipsychotics listed in Appendix 1 have been ineffective, are not tolerated, or are contraindicated.
  
- II. Administration and Authorization Period
  - A. Regence pharmacy services considers oral high-cost antipsychotics medications in this policy to be self-administered medications.
  - B. Authorization may be reviewed at least annually to confirm that current medical necessity criteria are met and that the medication is effective.

## Position Statement

- There are many generic atypical antipsychotic options available, of which generic olanzapine, quetiapine, risperidone, and ziprasidone are the lowest cost.
- Higher-cost antipsychotics, asenapine, brexpiprazole, cariprazine, iloperidone, lurasidone, paliperidone, and quetiapine ER, have not been established as superior in safety or efficacy relative to low-cost generic or preferred oral atypical antipsychotics but are more costly.
- There is a large body of evidence that indicates atypical antipsychotics are effective in certain conditions; however, because individual studies are unreliable, it cannot be determined if there is a clinically meaningful difference between individual medications. [1,2]
- No atypical antipsychotic has been shown to have an overall superior safety profile; however, individual medications differ in the incidence and severity of specific adverse events. [1,2]
- Appendix 1 includes examples of numerous low-cost, generically available treatment options for each diagnosis that high-cost antipsychotics are commonly used to treat.

## *Clinical Efficacy*

### SCHIZOPHRENIA

- Atypical antipsychotics, including low-cost generics, are all considered to be effective for treatment of schizophrenia. [1,2]
- With the exception of clozapine, there is no reliable evidence that one atypical antipsychotic is more effective than another. [1,2,5] Multiple systematic reviews and meta-analyses have been published to describe the comparative efficacy between atypical antipsychotics; however, these analyses are all based on low quality, unreliable evidence. Overall, the evidence for atypical antipsychotics in all conditions is considered generally low quality due to high attrition rates (up to 60%), small sample size, and lack of clinically meaningful endpoints.[1,2,5]
- Antipsychotics are recognized by guidelines as being effective for the treatment of schizophrenia. Atypical antipsychotics are generally preferred over first-generation (typical) antipsychotics due to the lower incidence of extrapyramidal side effects and tardive dyskinesia.[6-9]

- Guidelines recommend that treatment selection be guided by factors such as previous treatment response, adverse event profile, patient preference, route of administration, comorbid medical conditions and potential drug-drug interactions.<sup>[6-9]</sup>
- Guidelines recognize the superior efficacy of clozapine; however, due to risk of potentially serious blood dyscrasias, it is recommended only for treatment refractory disease.<sup>[6-9]</sup>

## BIPOLAR DISORDER

- Various atypical antipsychotics, including low-cost generics, have been studied for the treatment of bipolar disorder; however, there is insufficient evidence to determine comparable efficacy between products.<sup>[1,2]</sup>
- Guidelines recommend the use of generic mood stabilizers, as follows: <sup>[10-14]</sup>
  - \* For manic or mixed episodes, lithium carbonate or valproic acid with or without an antipsychotic as the preferred first-line treatment options. Carbamazepine and oxcarbazepine are listed as alternatives to lithium carbonate and valproic acid.
  - \* For depressive episodes, lithium with or without an antidepressant or lamotrigine as the preferred first-line treatment.

## MAJOR DEPRESSIVE DISORDER (MDD)

- Two large, comprehensive systematic reviews concluded that no atypical antipsychotic had evidence of providing a significant long-term benefit as an adjunct to antidepressants in treatment resistant depression.<sup>[1,2]</sup>
- Antidepressants such as selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), mirtazapine and bupropion, are recommended by guidelines as first line treatment for patients with major depressive disorder.<sup>[15]</sup>
- Because all antidepressants generally have similar efficacy, guidelines indicate choice of therapy should be guided by other factors such as adverse event profiles, half-life, potential drug-drug interactions, prior response and patient preference.<sup>[15]</sup>
- Guidelines recommend dose optimization, followed by transition to another antidepressant or augmentation with a second antidepressant, lithium carbonate, thyroid hormone, or an atypical antipsychotic.<sup>[15]</sup>

## AUTISTIC DISORDER

- There is limited evidence for the efficacy of pharmacotherapy in autistic disorder; however, SSRIs and atypical antipsychotics are used to alleviate some of the associated symptoms.<sup>[1,2,4,16]</sup>
- Two large, comprehensive systematic reviews concluded there is insufficient evidence to draw a conclusion regarding the efficacy of atypical antipsychotics for the treatment of autistic disorder.<sup>[1,2]</sup>
- Aripiprazole and risperidone have an FDA indication for irritability associated with autistic disorder.<sup>[3]</sup>

## Safety

- There is a general lack of useful data on the relative overall safety and tolerability of the atypical antipsychotics.
- Individual products vary in variety and severity of adverse events.<sup>[3]</sup>
- The most common adverse events to this class of medications are: <sup>[1-3]</sup>
  - \* Movement disorders and restlessness
  - \* Anticholinergic effects including sedation, blurry vision and dry mouth
  - \* Metabolic complications including weight gain, increased lipids and increased blood glucose
- Generally, treatments are selected based on side effect profiles and the impact on the patient's existing health status.<sup>[6-14]</sup>
- Use of atypical antipsychotics for dementia-related psychosis is associated with an increased risk of death and all medications in this class have a boxed warning with regard to use in this indication.<sup>[3]</sup>

## Appendix 1: Lowest-Cost Generic Medication Alternatives <sup>a</sup>

Class	Low-Cost Generic Preferred Alternatives
<b>Atypical antipsychotics</b>	<ul style="list-style-type: none"><li>- aripiprazole (generic Abilify<sup>®</sup>)</li><li>- clozapine (generic Clozaril<sup>®</sup>)</li><li>- olanzapine (generic Zyprexa<sup>®</sup>)</li><li>- quetiapine (generic Seroquel<sup>®</sup>)</li><li>- risperidone (generic Risperdal<sup>®</sup>)</li><li>- ziprasidone (generic Geodon<sup>®</sup>)</li></ul>

<sup>a</sup> Based on FDA-approval or guidelines. <sup>[3,6-16]</sup>

Cross References
None

Codes	Number	Description
N/A		

## References

1. McDonagh M, Peterson K, Carson S, et al. Drug Class Review: Atypical Antipsychotic Drugs: Final Update 3 Report [Internet]. Portland (OR): Oregon Available from <http://www.ncbi.nlm.nih.gov/books/NBK50583/>. Reviewed on 8/30/2016.
2. Shekelle P MM, Bagley S, Suttorp M, et al. Efficacy and Comparative effectiveness of Off-label Use of Atypical Antipsychotics. Comparative Effectiveness Review No. 6. AHRQ Publication No. 07-EHC003-EF. Rockville, MD: Agency for Healthcare Research and Quality. January 2007. Available from: [http://effectivehealthcare.ahrq.gov/ehc/products/5/64/Atypical\\_Executive\\_Summary.pdf](http://effectivehealthcare.ahrq.gov/ehc/products/5/64/Atypical_Executive_Summary.pdf). Reviewed on 8/30/2016.

3. Facts & Comparisons 4.0 (electronic version, updated periodically). Wolters Kluwer Health, Inc.
4. Williams K, Wheeler DM, Silove N, Hazell P. Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD). *Cochrane Database Syst Rev.* 2010 Aug 4;(8):CD004677. PMID: 20687077.
5. Asenjo Lobos C, Komossa K, et al. Clozapine versus other atypical antipsychotics for schizophrenia. *Cochrane Database Syst Rev.* 2010 Nov 10;(11):CD006633. PMID: 21069690.
6. American Psychiatric Association: Practice Guideline for the Treatment of Patients with Schizophrenia Second Edition. *Am J Psychiatry* 2004;161:1-56.
7. American Psychiatric Association Guideline Watch (September 2009): Practice Guideline for the Treatment of Patients with Schizophrenia. Available at: <http://psychiatryonline.org/guidelines>. Reviewed on 8/30/2016.
8. Hasan, A, Falkai, P, Wobrock, T, et al. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 2: Update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects. *World J Biol Psychiatry.* 2013 Feb;14(1):2-44. PMID: 23216388
9. Hasan, A, Falkai, P, Wobrock, T, et al. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. *World J Biol Psychiatry.* 2012 Jul;13(5):318-78. PMID: 22834451
10. American Psychiatric Association: Practice Guideline for the Treatment of Patients with Bipolar Disorder, 2<sup>nd</sup> Edition. *Am J Psychiatry* 2002; 159:1-50.
11. American Psychiatric Association Guideline Watch (2004): Practice Guideline for the Treatment of Patients with Bipolar Disorder, 2<sup>nd</sup> Edition. Available at: <http://psychiatryonline.org/guidelines>. Reviewed on 8/30/2016.
12. Grunze, H, Vieta, E, Goodwin, GM, et al. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders: Update 2010 on the treatment of acute bipolar depression. *World J Biol Psychiatry.* 2010 Mar;11(2):81-109. PMID: 20148751
13. Grunze, H, Vieta, E, Goodwin, GM, et al. The World Federation of Societies of Biological Psychiatry guidelines for the biological treatment of bipolar disorders: update 2009 on the treatment of acute mania. *World J Biol Psychiatry.* 2009;10(2):85-116. PMID: 19347775
14. Grunze, H, Vieta, E, Goodwin, GM, et al. The World Federation of Societies of Biological Psychiatry guidelines for the biological treatment of bipolar disorders: update 2012 on the long-term treatment of bipolar disorder. *World J Biol Psychiatry.* 2013 Apr;14(3):154-219. PMID: 23480132
15. Practice guideline for the treatment of patients with major depressive disorder, third edition. Arlington (VA): American Psychiatric Association (APA); 2010 Oct. 152 p.
16. Treatment and management of ASD. In: Ministries of Health and Education. New Zealand Autism Spectrum Disorder Guideline. Wellington (New Zealand): Ministry of Health; 2008. p. 133-62. Available at: <https://www.health.govt.nz/system/files/documents/publications/asd-guideline-apr08.pdf>. Reviewed on 8/30/2016.

### Revision History

Revision Date	Revision Summary
10/13/2017	No change to criteria with this annual update.
12/16/2016	Change step therapy from two low-cost generic options (including oral antipsychotics, mood stabilizers, or antidepressants) to two low-cost generic oral antipsychotics.
10/14/2016	Remove aripiprazole from the policy